Guard Therapeutics International
Guard Therapeutics International AB is a Stockholm-based biopharmaceutical company focused on developing therapies for kidney-related diseases. The company operates as a public Swedish research and development organization centered on drug discovery, clinical development, and partnering for its pipeline assets.
Fiscal year 2025 · change from previous year
Development 2025–2025
Business
Share of revenueTherapeutic candidates and research programs aimed at kidney-related diseases.
Customers
Guard Therapeutics does not sell mass-market products; its economic counterparties are typically pharmaceutical partners, research collaborators, and clinical trial service providers. In a development-stage model, value is created through advancing drug candidates toward licensing, partnering, or eventual commercialization by another company.
Companies that may license or co-develop Guard Therapeutics' pipeline assets for kidney disease.
Universities, CROs, and specialist vendors that support discovery and trial execution.
Potential downstream partners that would market approved therapies after development.
Strategy
Guard Therapeutics' strategy is to advance its kidney-disease pipeline through research, clinical development, and external collaboration. For a small biotech, progress in development milestones and partner relationships is central because it determines access to funding, validation, and eventual commercialization pathways.
Clinical and preclinical progress is the main driver of value in a development-stage biotech.
External partners can provide capital, expertise, and commercialization reach.
Geography
The company is headquartered in Stockholm, Sweden, and its operations are organized from that base. As a development-stage biotech, its geographic footprint is driven more by where research, trials, and partnering activities are conducted than by product manufacturing or broad commercial sales.
Risks
The company faces the typical risks of development-stage biotech, where clinical outcomes, regulatory decisions, and financing needs can materially affect value. Because it has no disclosed product revenue in the provided period, execution risk is concentrated in pipeline progress, partner dependence, and the ability to fund long development timelines.
Drug candidates may not show sufficient efficacy or safety in trials.
Exposure: Pipeline value and future partnering potential
A pre-revenue biotech typically relies on external capital to fund R&D.
Exposure: Operating runway and shareholder dilution
Authorities may require additional data or reject applications.
Exposure: Time to market and commercialization prospects
Licensing and collaboration terms can determine access to resources and market reach.
Exposure: Development funding and downstream monetization
Accounting
Judgemental itemsMost biotech costs are expensed as incurred, shaping reported losses and comparability.
Impact: Operating result and cash burn
Any partnering income may be recognized over time or at milestones depending on contract structure.
Impact: Timing of reported revenue
Biotech companies often use equity incentives, affecting operating expenses and dilution analysis.
Impact: Personnel cost and EPS
Similar listed companies
Publicly listed companies with a comparable business focus.
Bactiguard Holding
BACTI-B · Health Care
Bactiguard Holding AB is a global MedTech company based in Stockholm, Sweden, specializing in the development of biocompatible technology to prevent infections associated with medical devices.
Hansa Biopharma
HNSA · Health Care
Hansa Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions.
Akebia Therapeutics, Inc.
AKBA · Pharmaceutical Preparations
Akebia Therapeutics is a U.S.-based biopharmaceutical company focused on kidney disease, with two commercial products and a pipeline aimed at rare kidney diseases and other renal-related indications.
Grace Therapeutics, Inc.
GRCE · Pharmaceutical Preparations
GT Biopharma, Inc.
GTBP · Pharmaceutical Preparations
Vera Therapeutics, Inc.
VERA · Pharmaceutical Preparations
Last updated: 24/09/2026